Denali Therapeutics, Inc. (DNLI)
19.30
+0.47
(+2.50%)
USD |
NASDAQ |
May 21, 16:00
17.50
-1.80
(-9.33%)
After-Hours: 19:59
Denali Therapeutics Research and Development Expense (TTM) : 406.40M for March 31, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Biogen, Inc. | 1.607B |
| Neurocrine Biosciences, Inc. | 1.049B |
| Arcturus Therapeutics Holdings, Inc. | 87.94M |
| Agenus, Inc. | 69.64M |
| Curis, Inc. | 26.16M |